KRAS and neoplasm: There was no significant association between neovascular PSMA expression and clinical or biological parameters such as TNM/UICC/AJCC stage, KRAS mutation status, primary or metastatic tumor, or tumor cell budding in the investigated cohort (all p > 0.05, Chi-Square/Fisher's exact test).